Open Orphan Plc
hVivo involved in First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19
By Elric Langton | 28th September 2021
Breaking news from down under ENA Respiratory is an Australian-based clinical-stage pharmaceutical company aiming to transform the treatment and prevention of respiratory infections. The aim is to develop a first-in-class nasal spray to prevent COVID-19 and other respiratory viral infections, announced today that it has engaged research partners PPD, Inc. and hVIVO, a division of Open Orphan, to conduct its Phase 2 studies. The self-administered nasal spray, INNA-051, is being developed to stimulate the innate immunity in the nose, where most respiratory viral infections begin. This announcement follows encouraging preliminary results from the ongoing Phase 1 study, supporting the decision to progress INNA-051 development to Phase 2 studies.
INNA-051 is a broad-spectrum antiviral, immunomodulatory nasal spray under clinical development for pre-and post-exposure prophylaxis of respiratory viral infections. INNA-051 has not been approved by the TGA oโฆ